1ivc › Citations

Structures of aromatic inhibitors of influenza virus neuraminidase.

Jedrzejas MJ, Singh S, Brouillette WJ, Laver WG, Air GM, Luo M
Biochemistry 34 3144-51 (1995)
Related entries: 1ivb, 1ivd, 1ive, 1ivf, 1ivg

Cited: 51 times
EuropePMC logo PMID: 7880809

Abstract

Neuraminidase (NA), a surface glycoprotein of influenza virus, is a potential target for design of antiinfluenza agents. The crystal structure of influenza virus neuraminidase showed that in the active site 11 residues are universally conserved among all strains known so far. Several potent inhibitors based on the carbohydrate compound 2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid (DANA) have been shown to bind to the conserved active site and to reduce virus infection in animals when administered by nasal spray. Inhibitors of this type are, however, rapidly excreted from physiological systems and may not be effective in order to provide long-time protection. A new class of specific NA inhibitors, which are benzoic acid derivatives, has been designed on the basis of the three-dimensional structure of the NA-DANA complex and modeling of derivatives of 4-(acetylamino)benzoic acid in the NA active site. Intermediates were synthesized and were shown to moderately inhibit the NA activity and to bind to the NA active site as predicted. These rudimentary inhibitors, 4-(acetylamino)-3-hydroxy-5-nitrobenzoic acid, 4-(acetylamino)-3-hydroxy-5-aminobenzoic acid, and 4-(acetylamino)-3-aminobenzoic acid, and their X-ray structures in complexes with N2 (A/Tokyo/3/67) and B/Lee/40 neuraminidases have been analyzed. The coordinates of such inhibitors complexed with NA were used as the starting model for further design of more potent benzoic acid inhibitors. Because the active site residues of NA are invariant, the designed aromatic inhibitors have the potential to become an antiviral drug against all strains of influenza virus.

Articles - 1ivc mentioned but not cited (4)

  1. LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation. Huang B, Schroeder M. BMC Struct Biol 6 19 (2006)
  2. Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. von Grafenstein S, Wallnoefer HG, Kirchmair J, Fuchs JE, Huber RG, Schmidtke M, Sauerbrei A, Rollinger JM, Liedl KR. J Biomol Struct Dyn 33 104-120 (2015)
  3. PMFF: Development of a Physics-Based Molecular Force Field for Protein Simulation and Ligand Docking. Hwang SB, Lee CJ, Lee S, Ma S, Kang YM, Cho KH, Kim SY, Kwon OY, Yoon CN, Kang YK, Yoon JH, Nam KY, Kim SG, In Y, Chai HH, Acree WE, Grant JA, Gibson KD, Jhon MS, Scheraga HA, No KT. J Phys Chem B 124 974-989 (2020)
  4. Molecular-level simulation of pandemic influenza glycoproteins. Amaro RE, Li WW. Methods Mol. Biol. 819 575-594 (2012)


Reviews citing this publication (9)

  1. Pneumococcal virulence factors: structure and function. Jedrzejas MJ. Microbiol. Mol. Biol. Rev. 65 187-207 ; first page, table of contents (2001)
  2. Anti-influenza virus agents: synthesis and mode of action. Lagoja IM, De Clercq E. Med Res Rev 28 1-38 (2008)
  3. 'Flu' and structure-based drug design. Wade RC. Structure 5 1139-1145 (1997)
  4. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H. ChemMedChem 7 1527-1536 (2012)
  5. Neuraminidase inhibitors as anti-influenza virus agents. Kim CU, Chen X, Mendel DB. Antivir. Chem. Chemother. 10 141-154 (1999)
  6. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. J Prev Med Hyg 55 109-129 (2014)
  7. The influence of metals on the electronic system of biologically important ligands. Spectroscopic study of benzoates, salicylates, nicotinates and isoorotates. Review. Lewandowski W, Kalinowska M, Lewandowska H. J. Inorg. Biochem. 99 1407-1423 (2005)
  8. Approaches and strategies for the treatment of influenza virus infections. Colacino JM, Staschke KA, Laver WG. Antivir. Chem. Chemother. 10 155-185 (1999)
  9. Characterising non-covalent interactions with the Cambridge Structural Database. Lommerse JP, Taylor R. J. Enzym. Inhib. 11 223-243 (1997)

Articles citing this publication (38)

  1. Development and validation of a genetic algorithm for flexible docking. Jones G, Willett P, Glen RC, Leach AR, Taylor R. J. Mol. Biol. 267 727-748 (1997)
  2. GEMDOCK: a generic evolutionary method for molecular docking. Yang JM, Chen CC. Proteins 55 288-304 (2004)
  3. High throughput docking for library design and library prioritization. Diller DJ, Merz KM. Proteins 43 113-124 (2001)
  4. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB. Antimicrob. Agents Chemother. 42 3234-3241 (1998)
  5. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF. PLoS Pathog. 7 e1002249 (2011)
  6. Epitope analysis for influenza vaccine design. Muñoz ET, Deem MW. Vaccine 23 1144-1148 (2005)
  7. EUDOC: a computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases. Pang YP, Perola E, Xu K, Prendergast FG. J Comput Chem 22 1750-1771 (2001)
  8. Analysis of inhibitor binding in influenza virus neuraminidase. Smith BJ, Colman PM, Von Itzstein M, Danylec B, Varghese JN. Protein Sci. 10 689-696 (2001)
  9. An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Guo CT, Sun XL, Kanie O, Shortridge KF, Suzuki T, Miyamoto D, Hidari KI, Wong CH, Suzuki Y. Glycobiology 12 183-190 (2002)
  10. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. Du QS, Huang RB, Wei YT, Pang ZW, Du LQ, Chou KC. J Comput Chem 30 295-304 (2009)
  11. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Wu Y, Qin G, Gao F, Liu Y, Vavricka CJ, Qi J, Jiang H, Yu K, Gao GF. Sci Rep 3 1551 (2013)
  12. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. Birch L, Murray CW, Hartshorn MJ, Tickle IJ, Verdonk ML. J. Comput. Aided Mol. Des. 16 855-869 (2002)
  13. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site. Finley JB, Atigadda VR, Duarte F, Zhao JJ, Brouillette WJ, Air GM, Luo M. J. Mol. Biol. 293 1107-1119 (1999)
  14. Structurally conserved amino Acid w501 is required for RNA helicase activity but is not essential for DNA helicase activity of hepatitis C virus NS3 protein. Kim JW, Seo MY, Shelat A, Kim CS, Kwon TW, Lu HH, Moustakas DT, Sun J, Han JH. J. Virol. 77 571-582 (2003)
  15. Benzoic acid and pyridine derivatives as inhibitors of Trypanosoma cruzi trans-sialidase. Neres J, Bonnet P, Edwards PN, Kotian PL, Buschiazzo A, Alzari PM, Bryce RA, Douglas KT. Bioorg. Med. Chem. 15 2106-2119 (2007)
  16. A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. Jedrzejas MJ, Singh S, Brouillette WJ, Air GM, Luo M. Proteins 23 264-277 (1995)
  17. Hydrophobic benzoic acids as inhibitors of influenza neuraminidase. Atigadda VR, Brouillette WJ, Duarte F, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Sudbeck E, Finley J, Air GM, Luo M, Laver GW. Bioorg. Med. Chem. 7 2487-2497 (1999)
  18. Guanidinobenzoic acid inhibitors of influenza virus neuraminidase. Sudbeck EA, Jedrzejas MJ, Singh S, Brouillette WJ, Air GM, Laver WG, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Luo M. J. Mol. Biol. 267 584-594 (1997)
  19. Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents. Brouillette WJ, Bajpai SN, Ali SM, Velu SE, Atigadda VR, Lommer BS, Finley JB, Luo M, Air GM. Bioorg. Med. Chem. 11 2739-2749 (2003)
  20. Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors. Yi X, Guo Z, Chu FM. Bioorg. Med. Chem. 11 1465-1474 (2003)
  21. A novel approach to local similarity of protein binding sites substantially improves computational drug design results. Ramensky V, Sobol A, Zaitseva N, Rubinov A, Zosimov V. Proteins 69 349-357 (2007)
  22. Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping. Brouillette WJ, Atigadda VR, Luo M, Air GM, Babu YS, Bantia S. Bioorg. Med. Chem. Lett. 9 1901-1906 (1999)
  23. Letter Molecular docking, 3D-QSAR studies, and in silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors. Zhang J, Shan Y, Pan X, Wang C, Xu W, He L. Chem Biol Drug Des 78 709-717 (2011)
  24. Saturation transfer difference (STD) 1H-NMR experiments and in silico docking experiments to probe the binding of N-acetylneuraminic acid and derivatives to Vibrio cholerae sialidase. Haselhorst T, Wilson JC, Thomson RJ, McAtamney S, Menting JG, Coppel RL, von Itzstein M. Proteins 56 346-353 (2004)
  25. Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study. Yang Z, Yang G, Zhou L. J. Comput. Aided Mol. Des. 27 935-950 (2013)
  26. Inhibitory effect and possible mechanism of action of patchouli alcohol against influenza A (H2N2) virus. Wu H, Li B, Wang X, Jin M, Wang G. Molecules 16 6489-6501 (2011)
  27. Synthesis of a carbocyclic sialic acid analogue for the inhibition of influenza virus neuraminidase. Bianco A, Brufani M, Manna F, Melchioni C. Carbohydr. Res. 332 23-31 (2001)
  28. Molecular modeling of sialyloligosaccharide fragments into the active site of influenza virus N9 neuraminidase. Veluraja K, Suresh MX, Christlet TH, Rafi ZA. J. Biomol. Struct. Dyn. 19 33-45 (2001)
  29. Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors. Hsu KC, Hung HC, Horng JT, Fang MY, Chang CY, Li LT, Chen IJ, Chen YC, Chou DL, Chang CW, Hsieh HP, Yang JM, Hsu JT. PLoS ONE 8 e56704 (2013)
  30. Potential New H1N1 Neuraminidase Inhibitors from Ferulic Acid and Vanillin: Molecular Modelling, Synthesis and in Vitro Assay. Hariono M, Abdullah N, Damodaran KV, Kamarulzaman EE, Mohamed N, Hassan SS, Shamsuddin S, Wahab HA. Sci Rep 6 38692 (2016)
  31. Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase. Li J, Zhang D, Zhu X, He Z, Liu S, Li M, Pang J, Lin Y. Mar Drugs 9 1887-1901 (2011)
  32. Synthesis and anti-influenza virus activity of novel pyrimidine derivatives. Hisaki M, Imabori H, Azuma M, Suzutani T, Iwakura F, Ohta Y, Kawanishi K, Ichigobara Y, Node M, Nishide K, Yoshida I, Ogasawara M. Antiviral Res. 42 121-137 (1999)
  33. Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6. Venkatramani L, Johnson ES, Kolavi G, Air GM, Brouillette WJ, Mooers BH. BMC Struct. Biol. 12 7 (2012)
  34. Development and testing of a de novo drug-design algorithm. Pellegrini E, Field MJ. J. Comput. Aided Mol. Des. 17 621-641 (2003)
  35. Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity. Li Y, Silamkoti A, Kolavi G, Mou L, Gulati S, Air GM, Brouillette WJ. Bioorg. Med. Chem. 20 4582-4589 (2012)
  36. Aromatic sialic acid analogues as potential inhibitors of influenza virus neuraminidase. Bianco A, Brufani M, Melchioni C. Farmaco 56 305-309 (2001)
  37. A study on catalytic and non-catalytic sites of H5N1 and H1N1 neuraminidase as the target for chalcone inhibitors. Hariyono P, Kotta JC, Adhipandito CF, Aprilianto E, Candaya EJ, Wahab HA, Hariono M. Appl Biol Chem 64 69 (2021)
  38. Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies. Singh S, Malhotra AG, Jha M, Pandey KM. Virusdisease 29 461-467 (2018)


Related citations provided by authors (3)

  1. Structure-Based Inhibitors of Influenza Viral Neuraminidase. A Benzoic Acid Lead with Novel Interaction. Singh S, Jedrzejas MJ, Air GM, Luo M, Laver WG, Brouillette WJ To be Published -
  2. Benzoic acid inhibitors of influenza virus neuraminidase.. Luo M, Jedrzejas MJ, Singh S, White CL, Brouillette WJ, Air GM, Laver WG Acta Crystallogr D Biol Crystallogr 51 504-10 (1995)
  3. Three-Dimensional Structure of the Neuraminidase of Influenza Virus A(Slash)Tokyo(Slash)3(Slash)67 at 2.2 Angstroms Resolution. Varghese JN, Colman PM J. Mol. Biol. 221 473- (1991)

Quick links